# Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

> **NCT01712308** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 56 (actual)

## Conditions studied

- Anemia
- Myelodysplastic/Myeloproliferative Neoplasm
- Myelofibrosis

## Interventions

- **BIOLOGICAL:** Sotatercept
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT01712308
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-21
- **Primary completion:** 2022-05-24
- **Final completion:** 2022-05-24
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01712308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01712308, "Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01712308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*